Form Type: 4

SEC EDGAR Link
Accession Number:0000930413-19-003028
Date:2019-12-11
Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
Original Submission Date:

Reporting Person:

YANCOPOULOS GEORGE
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-11-18 G 325,986 a $0.00 325,986 direct
COMMON STOCK 2019-12-12 M 95,295 a $21.25 421,281 direct
COMMON STOCK 2019-12-12 F 49,405 d $377.16 371,876 direct
COMMON STOCK 2019-12-12 M 150,000 a $21.25 521,876 direct
COMMON STOCK 2019-12-12 F 77,767 d $377.16 444,109 direct
COMMON STOCK 2019-08-05 G 75,036 d $0.00 0 indirect
COMMON STOCK 2019-02-19 G 150,722 d $0.00 249,278 indirect
COMMON STOCK 2019-06-13 G 500,000 a $0.00 500,000 indirect
COMMON STOCK 2019-02-19 G 150,722 a $0.00 753,316 indirect
COMMON STOCK 2019-06-13 G 500,000 d $0.00 253,316 indirect
COMMON STOCK 2019-08-05 G 75,036 a $0.00 328,352 indirect
COMMON STOCK 2019-11-14 G 2,366 d $0.00 325,989 indirect
COMMON STOCK 2019-11-18 G 325,986 d $0.00 0 indirect
COMMON STOCK 2019-12-11 0 $0.00 5,791 indirect
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
CLASS A STOCK 0.0 2019-11-18 deemed execution date G 23,367 (a) common stock 23,367 $0.00 23,367 direct
CLASS A STOCK 0.0 2019-11-18 deemed execution date G 23,367 (d) common stock 23,367 $0.00 0 indirect by trust
NON-QUALIFIED STOCK OPTION (RIGHT TO BUY) 21.25 2019-12-12 deemed execution date M 95,295 (d) 2019-12-18 common stock 95,295 $21.25 150,000 direct
NON-QUALIFIED STOCK OPTION (RIGHT TO BUY) 21.25 2019-12-12 deemed execution date M 150,000 (d) 2019-12-18 common stock 150,000 $21.25 0 direct
NON-QUALIFIED STOCK OPTION (RIGHT TO BUY) 372.46 2019-12-11 deemed execution date A 81,278 (a) 2029-12-11 common stock 81,278 $372.46 81,278 direct
PERFORMANCE STOCK UNITS 0.0 2019-12-11 deemed execution date A 25,155 (a) common stock 25,155 $0.00 25,155 direct
CLASS A STOCK 0.0 2019-12-11 deemed execution date 0 ( ) common stock 5,383 $0.00 5,383 indirect by son
CLASS A STOCK 0.0 2019-12-11 deemed execution date 0 ( ) common stock 14,000 $0.00 14,000 indirect by daughter
Footnotes
IDfootnote
f1 disposition/acquisition made pursuant to a plan intended to comply with rule 10b5-1(c).
f2 class a stock of regeneron pharmaceuticals, inc. ("regeneron") converts to common stock of regeneron on a one-to-one basis upon certain events or upon election ofthe shareholder.
f3 these shares of class a stock are presently convertible and such conversion feature does not expire.
f4 these shares of class a stock are held in custody for the benefit of the reporting person's child.
f5 the stock option award (combined incentive stock option and non-qualified stock option) vested in four equal annual installments, commencing one year after the date ofgrant.
f6 the option became exercisable on december 31, 2012, based upon the satisfaction by the company of certain performance criteria during the period ended december 31,2012.
f7 the stock option award vests in four equal annual installments, commencing one year after the date of grant.
f8 each performance-based restricted stock unit ("psu") represents the contingent right to receive one share of the issuer's common stock at vesting. the amount reported reflects the maximum number of psus that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on december 11, 2023 and december 11, 2024, respectively. between 50% and 225% of the target number of psus (i.e., between 50% and 225% of 11,180 psus) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. if none of the performance metrics are achieved at the conclusion of the performance periods, the award expires.
WhaleWisdom Logo

Elevate your investments